- Home
- TAC vs TVTX Comparison
TAC vs TVTX Comparison
Compare TAC & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TAC | TVTX |
|---|---|---|
| Founded | 1909 | 2008 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.3B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | TAC | TVTX |
|---|---|---|
| Price | $12.51 | $27.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 15 |
| Target Price | $21.63 | ★ $37.21 |
| AVG Volume (30 Days) | 1.2M | ★ 3.2M |
| Earning Date | 02-19-2026 | 02-19-2026 |
| Dividend Yield | ★ 1.48% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,783,342,546.00 | $435,826,000.00 |
| Revenue This Year | N/A | $120.02 |
| Revenue Next Year | N/A | $37.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 114.22 |
| 52 Week Low | $7.82 | $12.91 |
| 52 Week High | $17.88 | $42.13 |
Technical Indicators
Market Signals| Indicator | TAC | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.75 | 28.62 |
| Support Level | $11.96 | $22.59 |
| Resistance Level | $12.63 | $40.75 |
| Average True Range (ATR) | 0.33 | 2.46 |
| MACD | 0.06 | -1.21 |
| Stochastic Oscillator | 46.58 | 29.46 |
Price Performance
Historical ComparisonAbout TAC TransAlta Corporation
TransAlta Corp is an independent power producer based in Alberta, Canada. The company operates a diverse and growing fleet of electrical power generation assets in Canada, the United States, and Australia. The company has six reportable segments namely, Hydro, Wind & Solar, Energy Marketing, Gas, Energy Transition segment and Corporate Segment. The company generates the majority of its revenue from the gas segment.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.